Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. Show more

Location: 3 More London Riverside, London, SE1 2RE, United Kingdom | Website: https://www.veronapharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

8.908B

52 Wk Range

$18.51 - $104.99

Previous Close

$104.85

Open

$104.85

Volume

10,918,722

Day Range

$104.79 - $104.93

Enterprise Value

68.8B

Cash

401.4M

Avg Qtr Burn

-30.04M

Insider Ownership

10.41%

Institutional Own.

90.98%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ohtuvayre (Ensifentrine-nebulized) Details Chronic obstructive pulmonary disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ensifentrine + glycopyrrolate Details Chronic obstructive pulmonary disease (“COPD”)	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ensifentrine (Nebulized) Details Non-cystic fibrosis bronchiectasis (bronchiectasis)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ensifentrine (Nebulized) Details Lung disease, Asthma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ensifentrine (Inhaled) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.